Latano-Vision (Latanoprost)

Latanoprost binds to FP receptors in the ciliary body, stimulating remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced outflow reduces intra‑ocular pressure, helping to prevent optic nerve damage associated with glaucoma.

The prescribed regimen for Latano-Vision is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but exact dosing and timing must follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the risk. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To order Latano-Vision, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Latano-Vision belongs to the prostaglandin analogue class, which generally offers once‑daily dosing and a strong intra‑ocular pressure‑lowering effect. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogues often achieve greater pressure reduction with a favorable dosing convenience, though individual response varies.

Store Latano-Vision at room temperature, below 25 °C, in the original container. Protect the bottle from direct light and moisture. Keep the dropper tip clean and avoid contaminating the solution. Do not freeze the product.

Latano-Vision is applied as an ocular solution. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively.

While most adverse events are mild, serious risks include severe allergic reactions such as eyelid swelling, rash, or anaphylaxis, and inflammatory eye conditions like uveitis or keratitis. Sudden loss of vision should be reported immediately. Patients should seek prompt medical attention if any of these occur.

Latano-Vision should not be used by individuals with known hypersensitivity to latanoprost or any of its excipients. Caution is advised for patients with active ocular infections, severe inflammation, or those who have had recent ocular surgery until cleared by their ophthalmologist.